- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: AZD1061 | COV2-2130 | Evusheld® (tixagevimab + cilgavimab)
cilgavimab is an approved drug (EMA (2022))
Compound class: Antibody
Comment: Cilgavimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2 . It was developed by AstraZeneca. This mAb blocks spike binding to ACE2 and prevents infection in animals. It is designed to be a long-acting agent, and in combination with tixagevimab (co-packaged combination= Evusheld®), is proposed as a therapeutic for those people who are likely to respond poorly to SARS-CoV-2 vaccines, or who cannot be vaccinated for any reason, including those who are immunocompromised . Data from the Phase 3 PROVENT trial (NCT04625725) show protection from infection that lasts for at least six months. AstraZeneca have reported that Evusheld® retains neutralising activity against the BA.1 omicron (B.1.1.529) SARS-CoV-2 variant. Cilgavimab as a single agent rmore effectively neutralises the BA.2 omicron subvariant than tixagevimab in vitro , so the combination retains neutralising activity.
1. Dong J, Zost SJ, Greaney AJ, Starr TN, Dingens AS, Chen EC, Chen RE, Case JB, Sutton RE, Gilchuk P et al.. (2021)
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail.
Nat Microbiol, 6 (10): 1233-1244. [PMID:34548634]
2. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K et al.. (2022)
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.
N Engl J Med, [Epub ahead of print]. DOI: 10.1056/NEJMc2201933 [PMID:35263535]
3. Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schäfer A, Reidy JX, Trivette A, Nargi RS et al.. (2020)
Potently neutralizing and protective human antibodies against SARS-CoV-2.
Nature, 584 (7821): 443-449. [PMID:32668443]